BECIDIGM
DEAD

Serial Number

88822042

Owner

Celgene Corporation

Attorney

Marilyn F. Kelly

Filing Date

Mar 5, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BECIDIGM Trademark

Serial Number: 88822042

BECIDIGM is a trademark filed by Celgene Corporation on March 5, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

March 5, 2020

Registration Date

Not Registered

Published for Opposition

July 20, 2021

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 21, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 21, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 24, 2024 EXRA
SOU EXTENSION 5 GRANTED
Feb 23, 2024 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 23, 2024 AITU
SOU EXTENSION 5 FILED
Feb 7, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Feb 7, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 31, 2023 EXRA
SOU EXTENSION 4 GRANTED
Aug 29, 2023 EX4G
SOU EXTENSION 4 FILED
Aug 29, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 29, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2023 EXRA
SOU EXTENSION 3 GRANTED
Mar 13, 2023 EX3G
SOU EXTENSION 3 FILED
Mar 13, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 13, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 25, 2022 EXRA
SOU EXTENSION 2 GRANTED
Aug 23, 2022 EX2G
SOU EXTENSION 2 FILED
Aug 23, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 23, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 25, 2022 EXRA
SOU EXTENSION 1 GRANTED
Feb 23, 2022 EX1G
SOU EXTENSION 1 FILED
Feb 23, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 23, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 14, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 20, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jul 20, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 30, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 10, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 11, 2020 GNFN
FINAL REFUSAL E-MAILED
Dec 11, 2020 GNFR
FINAL REFUSAL WRITTEN
Dec 11, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 24, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 23, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 23, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 29, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 29, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 29, 2020 CNRT
ASSIGNED TO EXAMINER
May 26, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 11, 2020 NWOS
NEW APPLICATION ENTERED
Mar 9, 2020 NWAP